Spruce Biosciences Secures $107M Cash, Extends Runway to H2 2027, Mitigating Going Concern Doubts
SPRB has more than doubled off its 52-week low of $4.35.
Summary
Spruce Biosciences reported a Q1 2026 net loss of $12.3 million, but critically announced a preliminary cash balance of $107.3 million as of April 30, 2026. This significant increase in cash, primarily from a recent underwritten public offering and a new term loan facility, extends the company's cash runway into the second half of 2027. This development directly addresses the 'substantial doubt about its ability to continue as a going concern' previously disclosed in the company's last 10-K filing. The extended runway provides crucial financial stability to support the planned Biologics License Application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Q4 2026 and its potential U.S. launch. Traders will now focus on the progress of the TA-ERT program and further updates on its regulatory pathway.
At the time of this announcement, SPRB was trading at $56.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $153.1M. The 52-week trading range was $4.35 to $240.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.